Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) EBIT (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed EBIT for 3 consecutive years, with -$21.9 million as the latest value for Q4 2025.

  • For Q4 2025, EBIT fell 20.06% year-over-year to -$21.9 million; the TTM value through Dec 2025 reached -$89.8 million, down 33.48%, while the annual FY2025 figure was -$89.8 million, 33.48% down from the prior year.
  • EBIT hit -$21.9 million in Q4 2025 for Artiva Biotherapeutics, up from -$22.9 million in the prior quarter.
  • Across five years, EBIT topped out at $12.7 million in Q4 2023 and bottomed at -$22.9 million in Q3 2025.
  • Average EBIT over 3 years is -$13.2 million, with a median of -$18.3 million recorded in 2024.
  • Year-over-year, EBIT tumbled 269.6% in 2024 and then decreased 20.06% in 2025.
  • Artiva Biotherapeutics' EBIT stood at $12.7 million in 2023, then crashed by 244.2% to -$18.3 million in 2024, then decreased by 20.06% to -$21.9 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$21.9 million, -$22.9 million, and -$22.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.